Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study With Meropenem

Gasparetto, Juliano; Pitta, Raphael Donadio; Cordova, Kassia; Kaczam, Katiana Garcia; Takara, Camila Mariye de Azevedo; Zanini, Guilherme Leite; Abujamra, Marcela; Cieslinski, Juliette; Tuon, Felipe Francisco

doi:10.1097/mjt.0000000000000955

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most important β-lactamases in P. aeruginosa are cephalosporinases, ampC hyper-expression, extended-spectrum β-lactamases, and carbapenemases. Currently, carbapenemases has been the major challenge, reducing therapeutic options to just a few, including old and toxic drugs (polymyxins and aminoglycosides) [ 97 , 98 , 99 , 100 , 101 , 102 ].…”

Section: Motility (Flagella and Type IV Pili)mentioning

confidence: 99%

Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pseudomonas aeruginosa is associated with several human infections, mainly related to healthcare services. In the hospital, it is associated with resistance to several antibiotics, which poses a great challenge to therapy. However, one of the biggest challenges in treating P. aeruginosa infections is that related to biofilms. The complex structure of the P. aeruginosa biofilm contributes an additional factor to the pathogenicity of this microorganism, leading to therapeutic failure, in addition to escape from the immune system, and generating chronic infections that are difficult to eradicate. In this review, we address several molecular aspects of the pathogenicity of P. aeruginosa biofilms.

show abstract

Section: Motility (Flagella and Type IV Pili)mentioning

confidence: 99%

Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some studies favored a shorter treatment time (approximately 7 days), with similar mortality and cure rates, despite the literature having a longer treatment time (above 10 days) for P. aeruginosa as a base rate 19,20 . In the hospital of the present study, shorter treatment ranging from 5 to 7 days is favored, even with aminoglycosides 21,22 . Since 2014 we have treated P. aeruginosa infection with aminoglycoside monotherapy using therapeutic drug monitoring successfully, even though some guidelines recommend combination therapy despite low evidence 21,23,24 .…”

Section: Discussionmentioning

confidence: 65%

“…19,20 In the hospital of the present study, shorter treatment ranging from 5 to 7 days is favored, even with aminoglycosides. 21,22 Since 2014 we have treated P. aeruginosa infection with aminoglycoside monotherapy using therapeutic drug monitoring successfully, even though some guidelines recommend combination therapy despite low evidence. 21,23,24 We are not in favor of monotherapy with aminoglycosides; however, we must have more scientific support, considering that these may be the only therapeutic option in some patients with carbapenemase-producing P. aeruginosa.…”

Section: Discussionmentioning

confidence: 99%

Pseudomonas aeruginosa in tracheal aspirate: Colonization, infection, and recurrence

Nunes

Lora

Cracco

et al. 2023

Clinical Respiratory J

Self Cite

View full text Add to dashboard Cite

Introduction Pseudomonas aeruginosa respiratory infections are challenging, and the risk of recurrence is a frequent problem. The aim of this study was to investigate the risk factors associated with the presence of P. aeruginosa, and the risk factors related to the recurrence and death of lower airway infections in inpatients in a Brazilian hospital. Methods Retrospective cohort with inpatients that had a sample of airways culture (tracheal aspirate or bronchoalveolar lavage) with the detection of P. aeruginosa. The patients with clinical criteria of infection were classified as ventilator‐associated, hospital‐acquired, or community‐acquired pneumonia. P. aeruginosa in respiratory samples without symptoms was considered colonization. The antimicrobial treatment adequacy and the clinical data were evaluated. Outcome variables included mortality and recurrence. Results One hundred and fifty‐four patients were included in the study, most of them were men, and the majority (102) were considered infected. The average length of stay was superior to 30 days. Previous pulmonary disease was associated with the occurrence of colonization. Aminoglycosides were the most active drug according to susceptibility tests and were successfully used as monotherapy. Septic shock was a risk factor for death in the infected patients. The use of adequate antimicrobial therapy was associated with major survival, independent of the infection classification. Conclusion It is possible to evaluate clinical data associated with recurrence and mortality in patients with different lung infections by P. aeruginosa. Aminoglycoside monotherapy is safe and effective in P. aeruginosa respiratory infections.

show abstract

“…Amikacin (AMK) and gentamicin are the most important antibiotics representing the group of aminoglycosides, and are characterized by their effect on most gram-negative bacteria [134]. The mechanism of action of these antibiotics involves binding to specific proteins of the 30S and 16S rRNA subunit, thereby, inhibiting protein synthesis, and assembly of the initiation complex related to mRNA [135].…”

Section: Aminoglycosidesmentioning

confidence: 99%

Antimicrobial Treatment of <i>Staphylococcus Aureus</i> Biofilms

Tuon¹,

Suss²,

Telles³

et al. 2022

Preprint

View full text Add to dashboard Cite

Staphylococcus aureus is a microorganism frequently associated with implant-related infections, owing to its ability to produce biofilms. These infections are difficult to treat because antimicrobials must cross the biofilm to effectively inhibit bacterial growth. Although some antibiotics can penetrate the biofilm and reduce the bacterial load, it is important to understand that the results of routine sensitivity tests are not always valid for interpreting the activity of different drugs. In this review, a broad discussion on the genes involved in biofilm formation, quorum sensing, and antimicrobial activity in monotherapy and combination therapy is presented that should benefit researchers engaged in optimizing the treatment of infections associated with S. aureus biofilms.

show abstract

Acute Kidney Injury in Patients Using Amikacin in Intensive Care Unit—A Paired Case–Control Study With Meropenem

Cited by 5 publications

References 9 publications

Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review

Pathogenesis of the Pseudomonas aeruginosa Biofilm: A Review

Pseudomonas aeruginosa in tracheal aspirate: Colonization, infection, and recurrence

Antimicrobial Treatment of <i>Staphylococcus Aureus</i> Biofilms

Contact Info

Product

Resources

About